Innovent Biologics has dosed the first participant in a Phase 3 study evaluating picankibart, an anti-IL-23p19 antibody, for psoriasis patients who had inadequate response to prior IL-17 inhibitor treatment.
Innovent's New Drug Application (NDA) for picankibart, an anti-IL-23p19 antibody, has been accepted by China's NMPA for treating moderate to severe plaque psoriasis.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.